Teva Just Borrowed $400M Without Giving Up a Single Share
Teva just secured $400 million from Blackstone without issuing a single share, using a royalty deal to fund a blockbuster IBD drug that could generate up to $5 billion in peak sales. It's the latest sign that royalty financing is reshaping how pharma funds its biggest bets.
The Art of Getting Money Without Losing Control
Imagine you're renovating your house. You could sell a room to fund the kitchen remodel, or you could strike a deal with an investor: "Help me pay for this, and I'll give you a small cut of the Airbnb revenue once it's done." Teva Pharmaceutical just did the corporate version of that.
The Israeli pharma giant locked in $400 million from Blackstone Life Sciences, spread over four years, to fund development of a promising inflammatory bowel disease (IBD) drug called duvakitug. No new shares issued. No ownership diluted. Instead, Blackstone gets a combination of milestone payments (triggered by FDA approval and commercial performance) plus low single-digit royalties on global sales. It's the biotech equivalent of paying your contractor with future rental income.
Why Duvakitug Has Everyone's Attention
Duvakitug isn't some early-stage science experiment. It's a monoclonal antibody (a lab-made protein designed to target a specific molecule in the body) that goes after a protein called TL1A. That protein is believed to crank up inflammation and drive scarring in the gut, which is exactly what makes Crohn's disease and ulcerative colitis so miserable for millions of people worldwide.
The drug is already in Phase 3 trials, the final and most expensive stage of testing before a company can ask the FDA for approval. And the Phase 2 data? Genuinely impressive. In extension studies announced in February 2026, patients with ulcerative colitis hit remission rates of 47% to 58% depending on dose, compared to placebo. For Crohn's disease, endoscopic improvement (meaning the gut lining actually looked better under a camera) reached 26% to 48%.
Those aren't incremental improvements. They're the kind of numbers that make analysts start throwing around the phrase "best-in-class."
Teva's $10 Billion Bet on Reinvention
To understand why this deal matters, you need to understand Teva's identity crisis. For decades, Teva was the king of generics: the company that made cheaper versions of everyone else's drugs. Profitable, sure, but not exactly glamorous. Think of it as being the store-brand cereal company in a world obsessed with artisanal granola.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Now Teva is executing what it calls its "Pivot to Growth" strategy, shifting toward branded specialty drugs with higher margins and bigger upside. Its existing branded products (Austedo, Ajovy, and Uzedy) already pulled in approximately $2.8 billion in sales, and the company posted $17.3 billion in total revenue for 2025.
But the real prize sits in the pipeline. Management projects duvakitug alone could hit peak annual sales of $2 billion to $5 billion, with total pipeline potential exceeding $10 billion. That's the kind of number that turns a generic drug company into a specialty pharma powerhouse.
The catch? Phase 3 trials are enormously expensive. And Teva is still working down a mountain of debt, targeting a leverage ratio of 2.0x adjusted EBITDA by 2028. Selling equity to fund trials would punish shareholders. Taking on more debt would slow deleveraging. The Blackstone royalty deal threads the needle perfectly.
Blackstone's Playbook: Fund It, Clip the Coupon
Blackstone Life Sciences isn't doing this out of charity. The firm has turned royalty financing into a repeatable formula: fund late-stage drugs where the science risk is mostly resolved, then collect a percentage of sales for years.
Their track record tells the story. In 2020, Blackstone funded Alnylam's Phase 3 trial for AMVUTTRA (a rare disease drug). Five years later, Royalty Pharma bought Blackstone's 1% royalty on that drug for $310 million. Not bad for backing a single clinical trial.
With Sutro Biopharma, Blackstone put up $140 million upfront, with another $250 million in potential milestones, in exchange for a 4% royalty on future sales. The pattern is consistent: find drugs close to the finish line, write a big check, and collect mailbox money if they succeed.
Duvakitug fits the mold. Phase 2 data is strong, Phase 3 is underway, and Sanofi is co-developing the drug. That's about as de-risked as late-stage biotech gets.
A Three-Way Partnership That Actually Makes Sense
The Sanofi angle is worth unpacking. Back in October 2023, Sanofi paid Teva $500 million upfront (with up to $1 billion in milestones) to co-develop and co-commercialize duvakitug. The two companies split development costs and profits equally in major markets. Sanofi leads Phase 3 development and commercialization in North America, Japan, and most of Asia; Teva handles Europe, Israel, and select countries.
So the architecture looks like this: Sanofi brings development expertise and commercial muscle in key markets. Blackstone brings $400 million in non-dilutive capital. Teva retains ownership, avoids dilution, and keeps its balance sheet moving in the right direction. Everyone has skin in the game, and everyone's incentives are aligned.
The Bigger Picture: Royalties Are Having a Moment
Teva's deal isn't happening in a vacuum. Royalty-based financing hit $10 billion in total transaction value in 2025, up 40% from the prior five-year average. Synthetic royalties (newly created royalties on pipeline drugs, as opposed to buying existing ones) accounted for nearly half that growth, reaching $4.7 billion.
Why the surge? Three forces are converging. Equity markets have been soft, making share issuances painful. Interest rates have made traditional debt more expensive. And late-stage drug development keeps getting pricier. Royalty financing offers a middle path: companies get capital without dilution, and investors get direct exposure to drug sales without owning volatile biotech stock.
For Teva specifically, the math is elegant. If duvakitug hits even the low end of its $2 billion peak sales estimate, Blackstone's low single-digit royalty could return multiples on its $400 million investment. And Teva gets to keep the vast majority of the economics while funding trials it couldn't easily afford through other channels.
The Competition Won't Wait
Duvakitug isn't the only anti-TL1A antibody in late-stage development. Merck's tulisokibart and Roche's afimkibart are both in Phase 3 trials, chasing the same IBD market. That market currently sits around $24 billion and is growing at roughly 5% per year.
The race matters because IBD treatments tend to be sticky: once a patient finds something that works, switching is rare. Whichever drug gets to market first (and with the best data) will have a significant first-mover advantage. The Blackstone funding ensures Teva and Sanofi won't be slowed down by a lack of capital.
Whether duvakitug ultimately earns $2 billion or $5 billion per year, one thing is clear: Teva just found a way to fund its biggest bet without betting the balance sheet. In a market where creative financing can be the difference between a drug that reaches patients and one that dies in development, that's a move worth watching.
4 min read
The Eczema Drug That Got Killed by a Cancer Signal
Kyowa Kirin just killed its most promising eczema drug after cancer cases emerged in clinical trials. The culprit? A mechanism that was supposed to be its biggest advantage may have been disabling the body's cancer defenses all along.
